On this page
A new skin concern has entered the market faster than almost any in recent memory, originating from a prescription drug. GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have become one of the most widely adopted drug classes in modern history. Gallup's most recent National Health and Well-Being Index1 found that 11% of US adults are currently taking a GLP-1 for weight loss, up from just 3% in 2024, with 15% reporting having used one at some point. That is a near-quadrupling of usage in two years, and adoption shows no sign of slowing.
The clinical benefits of these medications are well documented. But rapid, significant weight loss is now producing a widely reported cosmetic side effect: facial volume loss, sunken eyes, thinning lips, and skin sagging severe enough that clinicians and media alike have coined a term for it – "Ozempic face". According to a Cleveland Clinic-backed report covered by Healio, dermatologists attribute this to a combination of fat loss reducing structural support beneath the skin and a pace of weight loss that outstrips the skin's ability to retract and retain firmness.2, 3 Facial plastic surgeons interviewed for that same report describe patients who are thrilled with their new weight loss, but unsettled by what it has done to their face.
At in-cosmetics Global 2026 in Paris, "Ozempic face" was one of the most visible themes on the show floor, per BeautyMatter's show coverage4. Italian supplier Akott Evolution presented a reishi mushroom-derived adaptogen active positioned specifically against GLP-1-related skin laxity. Biotech company Debut has launched an AI-engineered elastin-boosting active, DermCeutical EDL, built to target what its founder describes as sudden-onset skin laxity distinct from ordinary age-related aging5. Analysts at Kantar6 have called this a "white-space growth opportunity", pointing to early entrants like Image Skincare's VOL.U.LIFT complex as proof that brands are already racing to claim this territory before larger, slower-moving legacy players catch up.
This is the real risk for formulators watching from the sidelines: this category is not waiting. Suppliers are launching targeted actives now; trade press is already covering "must-watch" ingredients for 2026, and consumer awareness of the term is at an all-time high. Brands and manufacturers who treat this as a future trend rather than a current one are likely to find the position already claimed by the time they act.
The mechanism behind Ozempic Face gives formulators a fairly clear technical brief: support structural volume, encourage collagen and elastin synthesis, and improve skin's ability to retract and firm after rapid fat loss. A few ingredient directions are gaining credible traction:
Suppliers, brands, and formulators researching this space should expect to see rapid iteration on these mechanisms over the next 12-18 months as more clinical data becomes available.
It is worth pausing on something slightly uncomfortable about this trend. The wellness and longevity conversation has spent the last several years moving deliberately away from "anti-aging" language toward "well-aging" — a shift toward accepting and supporting the skin through natural change rather than treating itself as a problem to be corrected. Ozempic face complicates that narrative. It is not really about aging at all, yet it is prompting exactly the kind of urgent, appearance-focused product response the well-aging movement has tried to move away from. There is something a little disheartening about an industry pivot this fast being driven by a medical side effect rather than a philosophy of care, even as the underlying formulation science is genuinely useful to the people experiencing it.
Millions of people currently have a skin concern that their existing routines, and in many many cases their brand's existing product lines, were not built to address. The suppliers and brands who source, formulate, and bring the credible, well-substantiated actives to market first are the ones most likely to own this category as it matures, much as early movers typically do in any ingredient-driven trend cycle.
If your pipeline doesn't yet answer for Ozempic Face, now is the time to start sourcing. Covalo's platform lets you search current supplier actives for firmness, elasticity, and skin barrier support in one place, so you can move on this before the window closes.
👉 Explore firming and elasticity ingredients on Covalo 👈
References